|会社名||ABIOMED Inc. （アビオメド）|
|分野（sector）||Health Care ヘルスケア|
|業種||先端医療機器_テクノロジ― 医療関連（Health Care）|
|概要||事業概要 アビオメッド(Abiomed Inc.)は機械的循環補助装置のプロバイダーであり、心不全患者向けに連続介護を提供する。同社は血流を改善、または心臓ポンプ機能を果たすことによって心臓を休息、治癒、回復させるように設計された製品を開発･製造･販売する。同社の製品は心臓カテーテル検査室で介入治療を行う心臓専門医に利用され、また心臓外科医が行う心臓手術スイートで血管形成術或は心臓外科手術前･中･後、予防的･緊急的に血行力学的補助を必要とする患者を対象に利用されている。平成24年9月、同社は最大6時間の局部的循環補助を提供する製品「Impella CP」が米国食品医薬品局（FDA）から510（k）認可を取得したと発表した。 アビオメドは、米国の医療装置メ―カ―。心不全患者の心臓回復治療に必要な循環補助装置や内蔵型循環補助装置、モニタリング装置を開発、製造、販売する。また、小型心臓ポンプや完全人工心臓の開発を手掛ける。米国内だけでなく、世界各国で製品の販売を行う。本社はマサチュ―セッツ州ダンバ―ス。 ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.|
|本社所在地||22 Cherry Hill Drive Danvers MA 01923 USA|
|代表者氏名||Michael R. Minogue マイケル・R・ミノーグ|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the three months ended 30 June 2018 ABIOMED Inc. revenues increased 36% to $180M. Net income increased from $37.4M to $90.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Investment income net increase from $635K to $1.6M (income) Other income (expense) net) increase from $79K to $188K (income).|
ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View 2020/01/14 06:22:00 Zacks Investment Research
ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.
10 Worst Performing S&P 500 Stocks Of 2019 2019/12/24 16:18:36 Benzinga Feeds
The S&P 500 had another big year this year, gaining more than 28% year to date. Most U.S. investors had a lot of winners in their portfolios this year, but not all companies were along for the bull market ride. Here’s a look at the 10 worst-performing stocks in the entire S&P 500 in 2019, as of the Dec. 20 closing price. 1. Fossil Group Inc (NASDAQ: FOSL ) Fossil investors have been on a rollercoaster ride in the past few years, and 2019 was mostly a free-fall, with the watchmaker’s stock dropping 51.1%. 2. ABIOMED, Inc. (NASDAQ: ABMD ) An FDA letter about the safety of ABIOMED’s Impella RP device wasn’t enough to eliminate market skepticism in 2019, and ABIOMED shares tumbled 49.8%. 3. Macy's Inc (NYSE: M ) Investors seem to be increasingly concerned that Macy’s is heading down the same long-term path as Sears Holdings … Full story available on Benzinga.com
Global Ventricular Assist Devices Market 2020-2024 | Evolving Opportunities with Abiomed Inc. and CorWave SA | Technavio 2019/12/03 14:00:00 Business Wire
LONDON--(BUSINESS WIRE)-- #Healthcare--Global ventricular assist devices market is poised to grow by USD 943.27 million during 2020-2024 at a CAGR of almost 12% during the forecast period.
Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA 2019/11/19 18:11:00 Benzinga Feeds
Abiomed (NASDAQ: ABMD ) is committed to improving patient outcomes by performing FDA studies and post-market surveillance, collecting real-world evidence and identifying and sharing best practices. Impella is the most studied mechanical circulatory support device in the history of the FDA with real-world clinical data on more than 110,000 patients in the Impella Quality (IQ) Database, FDA randomized controlled trials (RCT) and post-approval studies with greater than 5,000 patients, and more than 550 peer-reviewed publications. Impella is proven to provide superior hemodynamic support over the intra-aortic balloon pump (IABP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005932/en/ Figure 1: Clinical Variables Poorly Matched in Amin, et al. (Graphic: Business Wire) Today the Abiomed medical office is issuing a publication review of the observational analysis of Impella that was presented by Amin et al. at the American Heart Association Conference (AHA) on November 17.
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy? 2019/10/24 14:32:25 Zacks Investment Research
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abiomed, Inc. (ABMD) CEO Michael Minogue on Q1 2019 Results - Earnings Call Transcript 2019-05-02
Abiomed, Inc. (ABMD) Q1 2019 Earnings Conference Call May 02, 2019, 08:00 ET Company Participants Ingrid Ward - Director, IR Michael Minogue - Chairman, CEO & President Todd Trapp - CFO & VP Conference Call Participants Danielle Antalffy - SVB Leerink Bruce Nudell…
ABIOMED, Inc. 2019 Q4 - Results - Earnings Call Slides 2019-05-02
The following slide deck was published by ABIOMED, Inc. in conjunction with their 2019 Q4 earnings Read more …
ABMD, FLR and W among premarket losers 2019-05-02
Eventbrite (NYSE: EB ) -34% on Q1 earnings . More news on: Eventbrite, Inc., VistaGen Therapeutics, Inc., ABIOMED, Inc., Stocks on the move, Read more …
Abiomed on go with large study to assess Impella CP in STEMI heart attacks 2019-05-02
The FDA has signed off on a 668-subject clinical trial evaluating Abiomed's (NASDAQ: ABMD ) Impella CP heart pump in patients undergoing treatment for a type of heart attack called an ST-elevation myocardial infarction (STEMI). More news on: ABIOMED, Inc., Healthcare stocks news, Stock…